Tvardi Therapeutics to Participate in Upcoming Investor Conferences Feb 12, 2026 08:00AM
Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference Jan 8, 2026 04:05PM
Tvardi shares additional Phase 2 data showing fibrosis improvement Jan 8, 2026 08:03AM
Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights Jan 8, 2026 08:00AM
Tvardi Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference Nov 18, 2025 08:00AM


Nov 13, 2025 04:01PM Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update
Nov 4, 2025 08:00AM Tvardi Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
Oct 13, 2025 07:30AM Tvardi Therapeutics reports Phase 2 IPF trial did not meet goals
Oct 13, 2025 07:30AM Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis
Aug 21, 2025 08:00AM Tvardi Therapeutics to Participate in the Cantor Global Healthcare Conference
Aug 14, 2025 04:01PM Tvardi Therapeutics Announces Second Quarter 2025 Results and Provides Business Update
Jul 15, 2025 08:00AM Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
May 27, 2025 08:00AM Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis
May 20, 2025 08:00AM Tvardi Therapeutics to Participate in Upcoming Investor Conferences
May 13, 2025 04:05PM Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update
May 6, 2025 07:00AM Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference